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High-level expression of a heterologous protein in the milk of
transgenic swine using the cDNA encoding human protein C
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ABSTRACT Transgenic pigs were generated that pro-
duced human protein C in their milk at up to 1 g/liter. The
gene construct was a fusion gene consisting of the cDNA for
human protein C inserted into the first exon of the mouse whey
acidic protein gene. These results demonstrate that the mouse
whey acidic protein gene contains regulatory elements that can
direct cDNA expression at high levels in the pig mammary
gland. Recombinant human protein C that was produced at
about 380 pg/ml per hr in transgenic pig milk possessed
anticoagulant activity that was equivalent to that of protein C
derived from human plasma. These studies provide evidence
that y-carboxylation can occur at high levels in the mammary
gland of a pig.
Several different regulatory sequences have been identified
for milk protein genes that enable the expression of heterol-
ogous proteins in the milk of transgenic animals (1-4).
However, expression levels from cDNAs (1, 4) and genomic
sequences have been variable, with genomic sequences fre-
quently producing much higher levels of protein (2, 3). For
example, the cDNA encoding human factor IX (hFIX) was
expressed in sheep milk at only 25 ng/ml using a fusion gene
consisting of 4.0 kilobase pairs (kbp) of 5' flanking sequence
from the sheep /3-lactoglobulin gene (BLG), 1.5 kbp of hFIX
cDNA, and 4.9 kbp containing the BLG transcription unit
and 3' flanking sequence (1). In contrast, secretion of up to
30 mg/ml of human a1-antitrypsin (hAAT) into sheep milk
was achieved using the same 4.0 kbp of BLG 5' flanking
sequence fused to 6.5 kbp of hAAT minigene (first intron
removed) coding sequence (3). Additionally, there is no
direct correlation between the level of expression in trans-
genic mice compared to livestock for a given genetic con-
struct (2, 4). For example, transgenic pigs expressed a
7.2-kbp genomic fragment of mouse whey acidic protein
(WAP) at a 2- to 100-fold greater level (2, 5) than transgenic
mice with the same construct. Therefore, the choice of
employing a cDNA versus a genomic construct to synthesize
a given protein in the mammary gland of livestock can
become complex.
Human protein C (hPC) is a regulator of hemostasis,
suggesting its potential use as a therapy for many disease
states (6). Protein C is a zymogen of a serine protease that is
activated by thrombin (6). The structure of hPC is complex
and its level of expression in recombinant mammalian cells
(7) and transgenic mice (8) has been limited to <1 ,ug/ml per
hr. In this report, we detail the expression of functional
recombinant hPC (rhPC) in the milk of transgenic swine at
1000 ,ug/ml per hr using a hybrid genetic construct consisting
of the cDNA of hPC regulated by the mouse WAP gene.
MATERIALS AND METHODS
Transgenic Swine. Crossbred gilts served as embryo donors
and recipients of microinjected eggs. Estrus synchronization,
surgical procedures, and pronuclear microinjection of cen-
trifuged zygotes were performed as described by Wall et al.
(9). About 1-3 pl ofDNA solution (3.3 ,ug ofDNA per ml in
10mM Tris HCl/0.25 mM EDTA, pH 7.4) was microinjected
as described by Brinster et al. (10). The hybrid transgene
(WAPPC-1) consists of the cDNA for hPC inserted into the
unique Kpn I site in the first exon of the mouse WAP gene
(11), as illustrated in Fig. 1.
Tail tissue was biopsied from 2-day-old piglets and DNA
was isolated using a modification of the procedure developed
by Marmur (12). Transgenic founder animals were identified
initially by polymerase chain reaction (PCR) (13) using hPC-
specific primers and later confirmed by Southern analysis
using 32P-labeled hPC cDNA.
Mammary gland biopsies were performed on two trans-
genic females and a control female on days 55 and 35 of
lactation, respectively. Biopsies were washed briefly in ster-
ile saline and immediately frozen in liquid nitrogen. Total
RNA was isolated from the pig mammary gland biopsies and
human liver tissue samples (14). RNA samples (10 ,ug) were
fractionated using agarose/formaldehyde gels and then trans-
ferred by vacuum onto nylon membranes. The membranes
were probed with 32P random primer-labeled hPC cDNA or
WAP cDNA.
Pig Milk Collection and Preparation. Piglets were removed
from the sows for -30 min prior to milking to allow for milk
accumulation. Milk letdown was induced by intramuscular
administration of 20-30 international units of oxytocin. Milk
was collected directly into Tris-buffered saline/EDTA buffer
(2x TBS/EDTA: 100 mM Tris HCl, 300 mM NaCl, 200 mM
EDTA, pH 6.5, chilled to 0-2°C) in a 1:1 buffer to milk ratio.
Fat and precipitate were removed by centrifugation at 15,000
x g for 20 min at 0-2°C. The diluted whey was then filtered
through sterile gauze to remove residual solids and stored at
-90°C. Control pig milk was treated identically.
Analysis of rhPC. Expression levels in the whey were
determined by ELISA, using a monoclonal antibody (HPC4-
Mab) that has a calcium-dependent binding epitope in the
activation peptide (15). The rhPC captured by the HPC4-Mab
was detected using horseradish peroxidase conjugated to
goat anti-rabbit IgG following a 3-hr incubation at room
temperature with a rabbit polyclonal antibody to hPC. A
second ELISA procedure was also used in which rabbit
polyclonal anti-hPC antiserum was used to immunocapture
Abbreviations: hPC, human protein C; rhPC, recombinant hPC;
WAP, whey acidic protein; nt, nucleotide(s); APTT, activated partial
thromboplastin time; NRPP, normal reference plasma pool.
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FIG. 1. Diagram of the WAPPC-1 construct. The 1.6-kbp cDNA
for hPC [including 110 bases ofpoly(A)] was inserted at the Kpn I site
at the first exon ofWAP, using Kpn I linker DNA. The genomic WAP
gene consisted of 2.6 kbp of 5' flanking promoter sequence, 3.0 kbp
of coding sequence (exons and introns), and 1.6 kbp of 3' flanking
DNA. Noncoding DNA segments and introns are indicated by dark
lines. The open box is the linker DNA, the filled box is the cDNA for
hPC, and stippled boxes areWAP exons. PlasmidDNA was isolated,
digested with EcoRI, and purified using HPLC to remove all traces
of cloning vector DNA (8).
rhPC followed by detection with a sandwich ofgoat anti-hPC
antiserum and rabbit anti-goat antiserum conjugated to horse-
radish peroxidase.
The rhPC from transgenic pig whey was purified and
fractionated by using three successive immunosorptions by
HPC4-Mab immobilized onto Affi-Prep 10 (BioRad). Briefly,
the whey was diluted to 15 mg oftotal protein per ml and then
loaded onto the column in the presence of50mM Ca2+ in TBS
(pH 7.2) at 3-fold excess of column capacity assuming 0.2 mg
of hPC antigen per ml of immunosorbent. The rhPC that was
bound to the immunosorbent for each of three successive
immunodepletions of the starting whey was specifically
eluted with 50 mM EDTA in TBS (pH 7.2). The fall-through
from the first immunopurification was applied to the same
immunosorbent but at 10% of column capacity based upon
antigen levels detected by polyclonal ELISA. The fall-
through of the second immunopurification was adjusted to
pH 8.5 and applied to the HPC4-Mab immunosorbent at 10%
of column capacity based upon antigen levels detected by
polyclonal ELISA.
The biological activity of the rhPC was measured using an
activated partial thromboplastin time (APTT) assay (16). The
APTT reagent included Protac (Agkistrodon contortrix
venom, American Diagnostica, Greenwich, CT) to specifi-
cally activate hPC or rhPC prior to adding CaCl2 to initiate
coagulation.
RESULTS
DNA Analysis. A total of 26 piglets were born from 8
recipients that had received embryos microinjected with the
WAPPC-1 construct. Screening of genomic DNA from tail
biopsies using the PCR indicated that 7 piglets contained the
transgene, for an integration frequency of 27%6. Southern
analysis ofDNA from these pigs (Fig. 2A) identified only 5
positive for the transgene, including a male that died shortly
after birth (not shown in Fig. 2A). Assuming hemizygosity,
female founder animals 29-2, 83-1, 83-2, and 83-3 were
estimated (by PCR of serial DNA dilutions) to have 10, 20, 5,
and 1 copy of the transgene per genome, respectively (Table
1). Two other founder gilts (29-1 and 83-6) appeared to be
mosaic.
Southern blot analysis of tail DNA (digested with EcoRI,
which excises the entire WAPPC-1 transgene) from several
founder pigs is shown in Fig. 2A. Up to three bands hybrid-
ized with the hPC cDNA probe (lanes 6 and 7) and were
consistent with sizes ofmonomers, dimers, and trimers ofthe
transgene. DNA from other founder animals exhibited a
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Fio. 2. Southern analysis oftransgenic swine. DNA was isolated
from tail biopsies of 2-day-old piglets. DNA samples were digested
with EcoRI, run on 0.7% agarose gels, transferred to nitrocellulose
membranes, and hybridized with 32P random primer-labeled hPC
cDNA. Arrows indicate sizes of DNA bands in kbp. (A) Founder
animals. Lanes: 1-3, 250, 25, and 2.5 pg ofEcoRI-digested WAPPC-1
plasmid, respectively; 4-12, 5 pIg of EcoRI-digested DNA from
control pig and founder pigs 29-1, 29-2, 83-1, 83-2, 83-3, 83-4, 83-5,
and 83-6, respectively. (B) Pig 29-2 and offspring. Lanes: 1-4, same
as in A; 5, founder pig 29-2; 6-10, offspring from founder animal 29-2.
single band at about 9 kbp (lanes 8 and 11). Southern analysis
ofDNA from founder pig 29-2 and her offspring is presented
in Fig. 2B; three of five piglets contained the transgene.
Overall germ-line transmission of the transgene is summa-
rized in Table 1. Only one of the six founder females (83-6)
failed to transmit the transgene. Among 53 offspring from
transgenic founder animals, 28 contained the transgene, for
an overall frequency of germ-line transmission of 53%.
RNA Analysis. Northern blots of normal human liver RNA
and mammary gland RNA from pigs 29-1, 29-2, and control
were probed with 32P random primer-labeled hPC cDNA
(Fig. 3A). Human liver RNA (lanes 1, 2, 6, and 7) exhibited
a single weak band at about 1600 nucleotides (nt). A very
strong band of about 1480 nt was detected in RNA from pig
29-2 (lane 5) but not in RNA from the control pig (lane 3) or
transgenic pig 29-1 (lane 4). Additional weak bands of ap-
proximately 2360, 2630, and 4320 nt were detected in the
RNA ofpig 29-2 (lane 5) but not in the other pig RNA samples
nor the human RNA samples. Similar amounts of total RNA
(from both tissue types) were loaded onto the gel based on
18S and 28S rRNA band intensities. The hPC transcript
Table 1. Detection of transgenic founder animals, offspring, and
rhPC expression
hPC antigen, Ag/ml
Pig Gene copy Germ-line By HPC4-Mab By polyclonal
no.* no.t transmission* ELISA ELISA
29-1 <<1 6/9 2-3§ 1-3§
29-2 10 4/7 10-420§ 200-1000§
83-1 20 3/6 50-260§ 140-650§
83-2 5 9/12 ND 4-8
83-3 1 6/7 ND ND
83-6 <<1 0/12 0.5-1.0 2-5
ND, none detected.
*One transgenic male founder pig not included.
tTransgene copy number estimated by PCR analysis.
*Number of transgenic piglets per total number of piglets in first
litter.
§Expression levels detected over two 55-day lactations.
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FIG. 3. Northern analyses of pig mammary tissue and human
liver RNA. Arrows on the left indicate the positions of 18S and 28S
rRNA bands (1867 nt and 5025 nt, respectively); arrows on the right
indicate the estimated band sizes in nt. (A) Northern blot probed with
32P random primer-labeled hPC cDNA. (B) Northern blot probed
with 32P random primer-labeled WAP cDNA. Lanes: 1 and 2, 10 ,ug
of human liver total RNA isolated from two different liver samples;
3-5, 10 pg each of control pig, transgenic pig 29-1,.and transgenic pig
29-2 mammary gland total RNA, respectively; 6 and 7, replicate
samples of lanes 1 and 2.
appears to be about 100- to 1000-fold more intense in theRNA
from transgenic pig 29-2 mammary gland than in RNA from
human liver.
Northern analysis using 32P random primer-labeled WAP
cDNA as the probe (Fig. 3B) was done using the same RNA
samples as above. Bands corresponding to about 700 nt were
present in the mammary RNA of the control pig and trans-
genic pig 29-2 (lanes 3 and 5, respectively). In addition, two
very faint bands of about 2630 and 4320 nt in size were
detected in the RNA from pig 29-2 when probed with WAP
cDNA.
Protein Analysis. Antigen levels detected by ELISA using
polyclonal capture ranged from 200 ,ug/ml to 1000 .g/ml in
two lactations of pig 29-2 and from 140 ,ug/ml to 650 jg/ml
in two lactations of pig 83-1 (Table 1). ELISA using HPC4-
Mab immunocapture showed hPC antigen levels ranging from
10 ,ug/ml to 420 ,ug/ml and 50 ug/ml to 260 ,ug/ml in
transgenic pig milk from the first lactations of animals 29-2
and 83-1, respectively (Table 1). The antigen level detected
by either polyclonal or monoclonal ELISA steadily increased
during each lactation for pig 29-2 but was relatively constant
for pig 83-1 (data not shown). The milk from four additional
transgenic pigs exhibited hPC antigen levels ranging from
none detected to 8 ;&g/ml (by polyclonal capture ELISA).
Western blot analyses using WAP polyclonal antibody
showed that no WAP antigen was produced in the milk of
either control or transgenic pigs (data not shown).
Purification yields for successive immunosorption treat-
ments of starting whey from animal 29-2 (having 1 g of hPC
antigen per liter) are given in Table 2. The total HPC4-Mab
population capturable by these treatments represented 82%
of the total antigen detected by the polyclonal ELISA. The
first two immunosorption steps recovered about 63% of the
polyclonal rhPC population detected by ELISA, whereas the
successive immunosorption at pH 8.5 recovered an addi-
tional 9%o. About 15% of the polyclonal rhPC antigen was
detected in the third immunosorbent fall-through fraction.
The sum of residual hPC antigen in whey depleted by the
successive HPC4-Mab immunosorptions and the antigen
levels from each immunofraction totaled 97% of the antigen
detected in the starting whey. Recombinant protein C was
also purified from whey taken on different days of the first
two lactations for pig 29-2 and pig 83-1.
Coomassie blue-stained SDS/PAGE gels and Western blot
analysis (using polyclonal antisera for detection) ofwhey and
immunofractionated samples from milk (animal 29-2) having
1 g of hPC antigen per liter are presented in Fig. 4. The
starting whey (lane 2) is compared to rhPC obtained by two
successive immunopurifications using HPC4-Mab at pH 7.2
(lanes 3 and 4, respectively) followed by a third immunosorp-
tion at pH 8.5 (lane 5) and the remaining rhPC not immu-
nosorbed by the HPC4-Mab (lane 6). Comparison of the
scanning densitometries of Coomassie blue-stained SDS/
PAGE gels (Fig. 4A) with analogous Western analysis (Fig.
4C) indicated that all immunocaptured products were greater
than about 70%6 pure (Table 2). Some degradation of whey
proteins appeared to be present in the final affinity fall-
through fraction as evident by smearing in Coomassie blue-
stained SDS/PAGE gels under nonreducing and reducing
conditions (Fig. 4 A and B). Under nonreducing conditions
(Fig. 4C), the rhPC (lanes 2-6) migrated slightly faster than
hPC (lanes 1 and 7). An apparent molecular mass of about 58
kDa was seen for hPC and the molecular mass of the rhPC
was -55 kDa.
The Western blot analysis using reduced conditions re-
vealed several differences between the rhPC and hPC. (i) The
rhPC of starting material (Fig. 4D, lane 2) and immunoeluates
(lanes 3-5) contained more single-chain material than did
hPC (lanes 1 and 7). Table 2 presents the single-chain content
obtained by diffuse reflectance densitometry of Western
analysis from reduced SDS/PAGE. The single-chain content
Table 2. Purification of rhPC from transgenic pig whey containing 1 g of hPC antigen per liter
% single-chain Anticoagulant activityj
Step % hPC antigen recovered* % purityt contentt units/mg
Startingwhey 100 5 <1 37 5 ND
Immunofraction 1 38 + 3 >70 30 ± 5 291 + 5
Immunofraction 2 25 ± 5 >70 32 ± 6 107 ± 12
Immunofraction 3 19 ± 6 >70 24 ± 4 88 ± 15
Fall-through from eluate 3 15 ± 5 <1 3 ± 0.6 ND
hPC reference >90 3 ± 0.1 271 ± 8
ND, not determined due to high background activity.
*Polyclonal antigen ELISA values with standard errors from three dilutions of a single sample.
tCalculated from densitometric comparison of Western analysis and 0.125% Coomassie-stained SDS/PAGE gels under
nonreduced conditions for two replicate applications.
tStandard errors as calculated from delay in APTT for two dilutions of a single purification product.
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FIG. 4. SDS/PAGE and Western analysis of rhPC from the second lactation of transgenic pig 29-2. Nonreducing conditions (A and C) and
reducing conditions (B and D) are shown for SDS/PAGE and Western blot, respectively. Whey was prepared from milk collected on day 53
of lactation. Purified samples were applied with 5 ,ug of hPC antigen per well under nonreducing conditions (A) and 7 pg of hPC antigen per
well under reducing conditions (B); starting whey and final affinity fall-through with -1 .tg of hPC antigen and 50 j.g of total protein is evident
for nonreducing (A) and reducing (B) conditions. Samples analyzed by Western blot were applied with 200 ng of hPC antigen per well under
nonreducing conditions (C) and 300 ng of hPC antigen per well under reducing conditions (D). Arrows indicate positions of molecular mass
standards in kDa; M, molecular mass standard mixture. Lanes: 1 and 7, American Red Cross reference hPC immunopurified from normal pooled
donor plasma (lot no. 28309018); 2, starting whey (day 53); 3, immunofraction 1 obtained by loading starting whey at pH 7.2 using an estimated
3-fold overload of immunosorbent capacity; 4, immunofraction 2 obtained by loading of first fall-through at pH 7.2 using 10% of immunosorbent
capacity; 5, immunofraction 3 obtained by loading of second fall-through at pH 8.5 using 1o of immunosorbent capacity; 6, final affinity
fall-through from third loading. SC, single-chain hPC forms; HC, heavy-chain hPC forms; LC, light-chain hPC forms.
was similar in the starting whey (lane 2) and the first two
immunosorption eluates (lanes 3 and 4) with about 30-37%
single chain. However, the eluate from the HPC4-Mab im-
munosorption at pH 8.5 (lane 5) and the remaining fall-
through fraction (lane 6) contained less single chain-24%
and 3%, respectively. hPC contained only 3% single-chain
species (lanes 1 and 7). (ii) The molecular mass ofthe putative
heavy-chain forms ofrhPC (about 35-38 kDa) were about 2-3
kDa lower than that ofhPC (about 36-40 kDa). The molecular
mass of the light chain of rhPC was about 18-20 kDa and
appeared to be about 1-2 kDa lower than that of hPC. The
molecular mass of the single chain of rhPC was about 55-58
kDa and appeared to be about 1-3 kDa lower than that of
hPC.
Table 2 presents the specific anticoagulant activity based
upon delay in APTT due to increasing amounts of normal
reference plasma pool (NRPP), purified hPC from NRPP, and
rhPC obtained by successive immunosorptions from whey
(day 53, second lactation, pig 29-2) containing 1 g of rhPC
antigen per liter. The theoretical specific anticoagulant ac-
tivity of hPC in NRPP is 250 units/mg by definition (7, 16).
The specific anticoagulant activity of 271 ± 8 units/mg was
determined for hPC immunopurified from NRPP (Fig. 4,
lanes 1 and 7). The specific anticoagulant activity of rhPC
from the first immunosorption (Fig. 4, lane 3) was determined
to be 291 ± 5 units/mg. The specific anticoagulant activity of
rhPC from the second immunosorption (Fig. 4, lane 4) was
determined to be 107 ± 12 units/mg. The specific anticoag-
ulant activity of rhPC from the immunosorption at pH 8.5
(Fig. 4, lane 5) was determined to be 88 ± 12 units/mg. The
specific anticoagulant activity of recombinant protein C
(corresponding to immunofraction 1 and having a 30-60%o
recovery of hPC antigen predicted by polyclonal ELISA)
from milk obtained on different days of lactation from the first
and second lactations of pigs 29-2 and 83-1 ranged from 70o
to 150% of that obtained for hPC reference material (data not
shown).
DISCUSSION
Analysis of Southern blots of DNA from pig 29-2 and
offspring revealed different banding patterns among the piglet
DNA. Upon complete digestion, these bands could be re-
duced to a single band (data not shown). DNA from the
offspring of pig 29-2 had different banding patterns and
intensities. The banding pattern ofDNA from only one ofthe
piglets resembled that ofthe parent. Transgene insertion into
multiple chromosomes seems to have occurred for founder
pig 29-2, resulting in differing copy numbers being inherited
by the offspring. Judging from the banding patterns and
intensities observed for the piglet DNA, integration in sow
29-2 appears to have occurred on at least three chromosomes,
with different copy numbers at each insertion site.
Northern analyses (Fig. 3 A and B) showed the presence of
a major transcript of about 1480 nt was detected (when
hybridized with the hPCcDNA probe) in the RNA ofpig 29-2.
In the human liver RNA sample, a single band of 1600 nt was
detected. The relative amounts of hPC mRNA from pig 29-2
mammary gland and human liver hPC mRNA agree with the
relative amounts of protein C produced by the two tissues. In
pig 29-2 RNA, another band of about 2360 nt was specific for
hPC only. Other transcripts of about 2630 and 4320 nt (very
faint) were detected in both Northern blots, indicating they
may be read-through transcripts containing hPC and WAP
sequences.
In the present study, the mouse WAP gene was used to
direct the expression of the hPC cDNA into the milk of
transgenic swine, at levels that were about 1000-fold greater
in transgenic pigs than in transgenic mice containing the same
construct (8). This result was notable because in previous
Proc. Natl. Acad Sci. USA 89 (1992)
Proc. Natl. Acad. Sci. USA 89 (1992) 12007
studies high-level production ofheterologous proteins in milk
was achieved only in transgenic animals carrying either
genomic (2, 17) or minigene constructs (3). Our results show
that a cDNA may be used to obtain high-level expression of
heterologous proteins in the milk of transgenic pigs.
The highest expression levels of rhPC in the milk of
transgenic pigs using the cDNA of hPC were similar to the
expression levels reported for the WAP using the intact
genomic mouse WAP gene in transgenic pigs (2). A constant
level of WAP of about 1 g/liter was found in milk of
transgenic pigs over a 26-day lactation (17); rhPC (polyclonal
population) increased about 2-fold during the first 26 days and
>5-fold during the entire 55-day lactation ofpig 29-2, whereas
the rhPC in the milk of pig 83-1 varied about 2.5-fold. Since
WAP and rhPC transgenic pigs contained about 10-20 copies
ofthe transgene, differences in regulation may have been due
to the location of integration as well as the differences
between the WAP and WAP-hPC gene structures.
The molecular mass of the single, heavy, and light chains
of rhPC appeared to be similar to, but slightly lower than,
those for hPC. This may be due to differences in carbohy-
drate content and structure. The rhPC contained a signifi-
cantly larger population of single-chain material, which may
indicate a rate limitation in posttranslational removal of the
dipeptide Lys-Arg at positions 156 to 157 (7).
The presence of different rhPC populations was also evi-
dent from the differences in antigen content detected by
polyclonal and HPC4-Mab ELISAs and the presence of
different immunofractions obtained using the HPC4-Mab.
The HPC4-Mab binds the activation peptide ofhPC at pH 7.3
and thus provides a measure of the presentation of a domain
essential for conversion of zymogen hPC to active serine
protease form (15). Each of the immunofractions possessed
different anticoagulant activities, but activity did not corre-
late well with single-chain rhPC content. The most active
fraction represented about 38% of the hPC antigen and
contained 30% single-chain material. This suggests that a
significant portion of the single-chain material contained in
this fraction may be biologically active or that some het-
erodimeric forms are hyperactive. The lower activities of the
second and third fractions may be a result of nonnative
conformations or insufficient y-carboxylation.
The anticoagulant activity of protein C is dependent upon
proper y-carboxylation ofthe membrane binding domain that
occurs in the light chain (18). To determine whether y-car-
boxylation had occurred properly in rhPC, its anticoagulant
activity was assayed in vitro by APTT. This assay simulates
coagulation in vivo by initiating clotting in a mixture con-
taining calcium, phospholipid membrane, and the proteins
associated with hemostasis (16). As much as 38% (or 380
,ug/ml) of the porcine rhPC may be sufficiently -carboxy-
lated, as judged by the specific activity of immunofraction 1
by APTT relative to that of hPC. The transgenic pigs studied
here had milk letdown about every hour and hence the
maximum rhPC secretion rate occurred at about 1000 .ug/ml
per hr. The amount ofactive rhPC secreted by the pigs (about
380 I&g/ml per hr) is significantly higher than the secretion
rates of about 1 ,ug/ml per hr produced by human kidney 293
cell lines (7). These results provide evidence of gla formation
not previously known to occur at high levels in mammary
tissue.
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